Specialty biopharma Emergent Biosolutions Inc EBS has seen its stock rise more than 40 percent over the past two years, and investors shouldn't expect to see such outsized returns going forward, according to Wells Fargo.
Emergent Biosolutions' Stock Run Can't Continue Forever, Wells Fargo Says In Downgrade
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться